Skip to content

TCGA 2012 — comprehensive genomic characterization of LUSC

One-paragraph summary

The Cancer Genome Atlas profiled 178 lung squamous cell carcinomas using exome sequencing, copy-number analysis, messenger RNA, microRNA, promoter methylation, and selected whole-genome sequencing. It established LUSC as a highly altered, smoking-associated cancer dominated by TP53 disruption, copy-number change, tumour-suppressor loss, oxidative-stress, PI3K, squamous-differentiation, and chromatin pathways—not a single recurrent kinase addiction. The paper turned LUSC from a morphology-defined disease into a molecularly structured research field while simultaneously explaining why adenocarcinoma-style one-driver/one-drug precision oncology would be difficult.

Design and cohort

Element Detail
Cohort 178 surgically resected LUSCs with integrated molecular data
Platforms Exome, copy number, mRNA, microRNA, methylation; selected whole genomes
Comparator logic Recurrent events, pathway aggregation, expression/methylation integration
Clinical context Predominantly resected disease; not a randomized therapeutic cohort
Primary contribution Genomic atlas and candidate pathway definition

Key findings

  • TP53 alteration was near ubiquitous.
  • Recurrent pathway disruption involved CDKN2A/RB1 cell-cycle control, NFE2L2/KEAP1/CUL3 oxidative stress, PI3K signalling, squamous differentiation, and chromatin regulation.
  • Copy-number gains and losses were prominent; SOX2/TP63 lineage amplification and FGFR1 amplification were among high-interest events.
  • Potentially targetable alterations were distributed across multiple low-frequency classes rather than concentrated in one dominant driver.
  • The molecular landscape differed materially from lung adenocarcinoma.

What it did not show

  • It did not prove that any recurrent alteration was an oncogenic dependency in patients.
  • It did not test a targeted therapy or establish a predictive biomarker.
  • Resected primary tumours underrepresent late-stage evolution, metastatic heterogeneity, and treatment resistance.
  • Bulk profiling averages cancer, immune, stromal, and spatially distinct clones.
  • “Potentially targetable” reflected 2012 biological annotation, not clinical actionability.

Why it matters

This is the load-bearing molecular reference for LUSC. Nearly every later target program—FGFR, PI3K, DDR2, cell cycle, oxidative-stress metabolism, and antigen-presentation work—starts from this map. Its most important lesson is negative but productive: prevalence is not dependency. Lung-MAP and modern biomarker-defined trials are structural responses to the fragmentation TCGA documented.

Cited by wiki pages

  • Overview
  • Molecular landscape
  • Failed and frontier targets
  • Biomarkers
  • Guidelines

Verified citation

Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–525. [PMID 22960745](https://pubmed.ncbi.nlm.nih.gov/22960745/){target="_blank" rel="noopener"}